Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer

Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer

<em>Background</em>: Single-agent capecitabine (C) is a moderately effective chemotherapeutic compound in the treatment of patients with HER2-negative metastatic breast cancer (mBC). The capecitabine-vinorelbine (CV) combination is also used due to a good tolerability profile, but no stu...

Full description

Bibliographic Details
Main Authors: Claudio Vernieri, Michele Prisciandaro, Federico Nichetti, Riccardo Lobefaro, Giorgia Peverelli, Francesca Ligorio, Emma Zattarin, Maria Silvia Cona, Pierangela Sepe, Francesca Corti, Sara Manglaviti, Marta Brambilla, Barbara Re, Antonino Belfiore, Giancarlo Pruneri, Luigi Celio, Gabriella Mariani, Giulia Valeria Bianchi, Licia Rivoltini, Giuseppe Capri, Filippo de Braud
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
advanced breast cancer
chemotherapy
capecitabine
vinorelbine
hormone receptor-positive breast cancer
triple-negative breast cancer
progression-free survival
overall survival
adverse events
Online Access:https://www.mdpi.com/2072-6694/12/3/617

Internet

https://www.mdpi.com/2072-6694/12/3/617

Similar Items